In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents

被引：195

作者：

Almyroudis, Nikolaos G.

Sutton, Deanna A.

Fothergill, Annette W.

Rinaldi, Michael G.

Kusne, Shimon

机构：

[1] Roswell Pk Canc Inst, Dept Med, Buffalo, NY USA

[2] Dept Pathol, Fungus Testing Lab, San Antonio, TX USA

[3] Audie L Murphy Mem Vet Adm Med Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX USA

[4] Mayo Clin, Phoenix, AZ USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2007年 / 51卷 / 07期

关键词：

D O I：

10.1128/AAC.00452-07

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We evaluated the in vitro susceptibilities of 217 zygomycetes to amphotericin B, ketoconazole, fluconazole, itraconazole, voriconazole, posaconazole, caspofungin, and flucytosine. The significant in vitro activity of posaconazole against several species appears to support its reported clinical efficacy. Decreased susceptibility to amphotericin B was noted with Cunninghamella bertholletiae.

引用

页码：2587 / 2590

页数：4

共 30 条

[1] Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature
Almyroudis, N. G.
Sutton, D. A.
Linden, P.
Rinaldi, M. G.
Fung, J.
Kusne, S.
[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (10) : 2365 - 2374
[2] [Anonymous], CLIN MYCOLOGY
[3] In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates
Arikan, S
Lozano-Chiu, M
Paetznick, V
Rex, JH
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) : 327 - 330
[4] Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans
Bekersky, I
Fielding, RM
Dressler, DE
Lee, JW
Buell, DN
Walsh, TJ
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) : 828 - 833
[5] Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi
Cuenca-Estrella, M
Gomez-Lopez, A
Mellado, E
Buitrago, MJ
Monzon, A
Rodriguez-Tudela, JL
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) : 917 - 921
[6] Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis
Dannaoui, E
Mouton, JW
Meis, JFGM
Verweij, PE
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) : 1953 - 1959
[7] Activity of posaconazole in treatment of experimental disseminated zygomycosis
Dannaoui, E
Meis, JFGM
Loebenberg, D
Verweij, PE
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) : 3647 - 3650
[8] In vitro susceptibilities of zygomycetes to conventional and new antifungals
Dannaoui, E
Meletiadis, J
Mouton, JW
Meis, JFGM
Verweij, PE
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (01) : 45 - 52
[9] Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi
Diekema, DJ
Messer, SA
Hollis, RJ
Jones, RN
Pfaller, MA
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (08) : 3623 - 3626
[10] Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment:: more evidence of the utility of azoles for zygomycosis
Eisen, DP
Robson, J
[J]. MYCOSES, 2004, 47 (3-4) : 159 - 162

← 1 2 3 →